Daniel Chung, DO, MA

Daniel Chung, DO

Chief Medical Officer

SparingVision

Biography

Dr. Chung was appointed Chief Medical Officer of SparingVision in February 2021. In his role, he leads the clinical development and research into SPVN06, SparingVision’s flagship development asset, and is responsible for the clinical development of current and future pipeline products. Dr. Chung also leads the education of the medical community and patient advocacy.
Prior to joining SparingVision as CMO, Dr. Chung led the global medical strategy for ophthalmology at Spark Therapeutics, a leading rare disease gene therapy company and a member of the Roche Group. He played a pivotal role in the clinical development and approval of Luxturna™, the first gene therapy to be approved in the US for a genetic disease. During his time at Spark he served as the inherited retinal disease and ophthalmology expert across various company divisions and worked in medical affairs, clinical development and patient advocacy. Prior to Spark, Dr. Chung worked for 11 years at the Scheie Eye Institute within the Perelman School of Medicine at the University of Pennsylvania, specialising in gene-based therapies for inherited retinal diseases and cilia mediated disease.
Dr. Chung received his medical degree from the New York College of Osteopathic Medicine in 1994 and undertook postgraduate training at the National Eye Institute, Summa Health Systems and Cole Eye Institute at the Cleveland Clinic Foundation.
Dr. Chung is based in Philadelphia, USA.

STAY UP TO DATE WITH OIS

STAY UP TO DATE WITH OIS

get the latest news & exclusive content!

get the latest news & exclusive content!